Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your product review and approval news for the week in brief: The US Food and Drug Administration has now cleared a dozen treatments under its Real-Time Oncology Review (RTOR) pilot program with approvals last week for Merck & Co. Inc. and Eisai Co. Ltd.'s Keytruda (pembrolizumab)/Lenvima (lenvatinib) combination and Janssen Pharmaceutical Cos.'s Erleada (apalutamide).

Another notable approval went to Novo Nordisk AS's oral semaglutide product Rybelsus for the treatment of type 2 diabetes,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers